Serum omentin-1 levels as a possible risk factor of mortality in patients with diabetes on haemodialysis

Diabetes Research and Clinical Practice

Volumn 110, Issue 1, 2015, Pages 44-50

  Kocijancic, Marija ^a   Vujicic, Bozidar ^b   Racki, Sanjin ^b   Cubranic, Zlatko ^b   Zaputovic, Luka ^b   Dvornik, Stefica ^b  

^a Health Care Center of Primorsko Goranska County   (Croatia)

^b KBC RIJEKA   (Croatia)

Author keywords

Diabetes mellitus; Dialysis; Omentin 1 protein

Indexed keywords

ADIPOCYTOKINE; INSULIN; OMENTIN 1; ORAL ANTIDIABETIC AGENT; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CYTOKINE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; ITLN1 PROTEIN, HUMAN; LECTIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DIABETIC PATIENT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OMENTIN 1 BLOOD LEVEL; PREDICTION; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; VENOUS BLOOD; ADVERSE EFFECTS; BLOOD; COMPLICATION; DIABETIC NEPHROPATHIES; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; CYTOKINES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GPI-LINKED PROTEINS; HUMANS; LECTINS; MALE; MIDDLE AGED; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84943201600     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2015.06.008     Document Type: Article

References (28)

1. Alcelik A., Tosun M., Ozlu M.F., Eroglu M., Aktas G., Kemahli E., et al. Serum levels of omentin in end stage renal disease patients. Kidney Blood Press Res 2012, 35(6):511-516. 10.1159/000338796.
2. Abdallah S., Ahmad A.T., Batieha A., Ajlouni K. Diabetes mellitus: the leading cause of hemodialysis in Jordan. East Mediterr Health J 2007, 13:803-809.
3. Shrishrimal K., Hart P., Michota F. Managing diabetes in hemodialysis patients: observations and recommendations. Cleve Clin J Med 2009, 76:649-655. 10.3949/ccjm.76a.09054.
4. Tsimihodimos V., Dounousi E., Siamopoulos C.K. Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment. Am J Nephrol 2008, 28:958-973. 10.1159/000144024.
5. Yao Q., Filiho P.R., Lindholm B., Stenvinkel P. Traditional and non-traditional risk factors as contributors to atherosclerotic cardiovascular disease in end stage renal disease. Scand J Urol Nephrol 2004, 38:405-416. 10.1080/00365590410031715.
6. Shoji T., Emoto M., Shinohara K., Kakiya R., Tsujimoto Y., Kishimoto H., et al. Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal disease. J Am Soc Nephrol 2001, 12:2117-2124.
7. Tsimihodimos V., Mitrogianni Z., Elisaf M. Dyslipidemia associated with chronic kidney disease. J Cardiovasc Med 2011, 5:41-48. 10.2174/1874192401105010041.
8. Zhou J.Y., Chan L., Zhou S.W., Omentin Linking metabolic syndrome and cardiovascular disease. Current Vascular Pharmacology 2014, 12:136-143. 10.2174/1570161112999140217095038.
9. Yamawaki H. Vascular effects of novel adipocytokines: focus on vascular contractility and inflammatory responses. Biol Pharm Bull 2011, 34:307-310. 10.1248/bpb.34.307.
10. Tan K.B., Adya R., Randeva S.H. Omentin: a novel link between inflammation, diabesity, and cardiovascular disease. Trends Cardiovasc Med 2010, 20:143-148. 10.1016/j.tcm.2010.12.002.
11. Moreno-Navarrete J.M., Ortega F., Castro A., Sabater M., Ricart W., Fernandez-Real J.M. Circulating omentin as a novel marker of endothelial dysfunction. Obesity 2011, 19:1552-1559. 10.1038/oby.2010.351.
12. Yang R.Z., Lee M.J., Hu H., Pray J., Wu H.B., Hansen C.B., et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006, 290:1253-1261. 10.1152/ajpendo.00572.2004.
13. Liu R., Wang X.L., Bu P.L. Omentin-1 is associated with carotid atherosclerosis in patients with metabolic syndrome. Diabetes Res Clin Pract 2011, 93:21-25. 10.1016/j.diabres.2011.03.001.
14. Moreno-Navarrete J.M., Catalan V., Ortega F., Gomez-Ambrosi J., Ricart W., Fruhbeck G., et al. Circulating omentin concentration increases after weight loss. Nat Metlab (Lond) 2010, 7:27. 10.1186/1743-7075-7-27.
15. Saremi A., Asghari M., Ghorbani A. Effects of aerobic training on serum omentin-1 and cardiometabolic risk factors in overweight and obese men. J Sports Sci 2010, 28:993-998. 10.1080/02640414.2010.484070.
16. Narumi T., Watanabe T., Kadowaki S., Kinoshita D., Yokoyama M., Honda Y., et al. Impact of serum omentin-1 levels on cardiac prognosis in patients with heart failure. Cardiovasc Diabetol 2014, 13:84-91. 10.1186/1475-2840-13-84.
17. Shibata R., Ouchi N., Kikuchi R., Takahashi R., Takeshita K., Kataoka Y., et al. Circulating omentin is associated with coronary artery disease in men. Atherosclerosis 2011, 219:811-814. 10.1016/j.atherosclerosis.2011.08.017.
18. Yang R.Z., Lee M.J., Hu H., Pray J., Wu H.B., Hansen B.C., et al. Identification of omentin as a novel depotspecific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006, 290:E1253-E1261. 10.1152/ajpendo.00572.2004.
19. Yamawaki H., Tsubaki N., Mukohda M., Okada M., Hara Y. Omentin, a novel adipokine, induces vasodilation in rat isolated blood vessels. Biochem Biophys Res Commun 2010, 393:668-672. 10.1016/j.bbrc.2010.02.053.
20. Yamawaki H., Kuramoto J., Kameshima S., Usui T., Okada M., Hara Y. Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells. Biochem Biophys Res Commun 2011, 408:339-343. 10.1016/j.bbrc.2011.04.039.
21. Gürsoy G., Kirnap G.N., Eşbah O., Acar Y., Demirbaş B., Akçayöz S., et al. The relationship between plasma omentin-1 levels and insulin resistance in newly diagnosed type 2 diabetic women. Clin Rev Opin 2010, 4:49-54.
22. Tan B.K., Pua S., Lewandowski K.C., O'Hare P., Randeva S.H. Decresed plasma omentin-1 levels in type 1 diabetes mellitus. Diabet Med 2008, 25:1251-1255. 10.1111/j 1464-5491.2008.02568.x.
23. Skrha J., Stulc T., Hilgertova J., Weiserova H., Kvasnicka J., Ceska R. Effect of simvastatin and fenofibrate on endothelium in type 2 diabetes. Eur. J Pharmacol 2004, 493:183-189. 10.1016/j.ejphar.2004.04.025.
24. Greulich S., Chen Y.J.W., Maxhera B., Rijzewijk J.L., Van der Meer W.R., Jonker T.J., et al. Cardioprotective properties of omentin-1 in type 2 diabetes: evidence from clinical and in vitro studies. PLOS ONE 2013, 8:1-11. 10.1371/journal.pone.0059697.
25. Tan B.K., Adya R., Farhatullah S., Lewandowski K.C., O'Hare P., Randeva S.H. Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes 2008, 57:801-808. 10.2337/db07-0990.
26. Strippoli M.F.G., Navaneethan D.S., Johnson W.D., Perkovic V., Pellegrini F., Nicolucci A., et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ 2008, 336:645-651. 10.1136/bmj.39472.580984.AE.
27. Pan H.Y., Guo L., Li Q. Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Res Clin Pract 2010, 88:29-33. 10.1016/j.diabres.2010.01.013.
28. Yan P., Liu D., Long M., Ren Y., Pang J., Li R. Changes of Serum omentin levels and relationship between omentin and adiponectin concentrations in type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2011, 119:257-263. 10.1055/s-0030-1269912.